ClinicalTrials.gg
CompletedNCT00771472Updated Apr 21, 2015Results posted

Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)

A Phase 1 interventional study of vorinostat in Lymphoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-04-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing vorinostat in Lymphoma — none open to participants now, 1 under way, 1 of them phase 3. Vorinostat · Lymphoma.

Enrollment
13th of 19
10 · median 17
Started
2008
with 2 others
Phase 1
7 of 20
none open now
Registered
6th of 20
by date
Lead sponsor
4 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing vorinostat in Lymphoma, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2008, is one of 7 in phase 1, and was the 6th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

None of the 20 studies testing vorinostat in Lymphoma is open now. The open studies under Lymphoma, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing vorinostat in Lymphoma as a file.
02

Study summary

Part I evaluates the safety, tolerability and pharmacokinetics (PK) of vorinostat in Japanese patients with relapsed or refractory CTCL. Part II evaluates the safety of vorinostat in Japanese pts. with relapsed or refractory CTCL. Relapsed or refractory CTCL patients will be newly enrolled in Part II.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients With CTCL Who Have Progressive, Persistent Or Recurrent Disease Subsequent To At Least One Prior Therapy
  • (ECOG) Performance Status Must Be 0-2
  • Patients Have Adequate Bone Marrow, Liver Function And Renal Function

Exclusion criteria

Exclusion Criteria (Parts I \& II):

  • Patients Had Prior Therapy Within 3 Weeks Before Registration, Or Have Not Recovered From Toxicities Of Prior Therapy
  • Patients Have Uncontrolled Intercurrent Illness
  • Pregnant Or Women Have A Will To Be Pregnant And Lactating Woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Vorinostat

    Drug: vorinostat

Interventions

  • Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.

    Also known as: MK-0683, Zolinza

06

What researchers measure

Primary outcomes

  1. Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE)

    A laboratory AE is defined as any unfavorable \& unintended change in the chemistry of the body temporally associated with the use of study product, whether or not considered related to the use of the product. A clinical AE is defined similarly but also includes changes in structure or function of the body.

    Time frame: Day 1 up until 30 days post study completion or early termination (up to approximately 506 days)

  2. Part I: Number of Participants Experiencing Dose Limiting Toxicity (DLT)

    A DLT was defined as any of the following (per Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0): * Grade 3 (severe)-4 (life-threatening) neutropenia with fever ≥ 38.5ºC * Grade 3-4 neutropenia with an infection requiring antibiotic or antifungal treatment * Grade 4 neutropenia lasting at least 5 days * Grade 4 thrombocytopenia * Other Grade 4 hematologic toxicity, including a decrease in hemoglobin, only at the discretion of the principal investigator * Grade 3 or 4 non-hematologic event, except which are manageable by supportive care or non-prohibited therapies

    Time frame: Day 1 to Day 28

Secondary outcomes

  1. Part I: Total Drug Exposure (Area Under the Concentration Curve, AUC[0-24 Hours])

    Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.

    Time frame: Days 1 & 28 of Cycle 1

  2. Part I: Maximum Drug Concentration (Cmax)

    Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.

    Time frame: Days 1 & 28 of Cycle 1

  3. Part I: Time at Which Cmax Occurs (Tmax)

    Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.

    Time frame: Days 1 & 28 of Cycle 1

  4. Part I: The Amount of Time it Takes for the Drug Concentration to Decrease by Half (T1/2)

    Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.

    Time frame: Days 1 & 28 of Cycle 1

07

Results

Posted Jul 4, 2012

Participant flow

Participant flow — Overall Study
MilestonePart IPart II
Started64
Completed00
Not completed64
Withdrew: Physician decision23
Withdrew: Progressive disease31
Withdrew: Protocol violation10

Outcome measures

PrimaryParts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE)

A laboratory AE is defined as any unfavorable \& unintended change in the chemistry of the body temporally associated with the use of study product, whether or not considered related to the use of the product. A clinical AE is defined similarly but also includes changes in structure or function of the body.

Time frame:
Day 1 up until 30 days post study completion or early termination (up to approximately 506 days)
Reported as:
Number · participants
Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE)
participantsVorinostat
Clinical AEs10
Laboratory AEs6
SecondaryPart I: Total Drug Exposure (Area Under the Concentration Curve, AUC[0-24 Hours])

Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.

Time frame:
Days 1 & 28 of Cycle 1
Reported as:
Geometric mean · µM*hr
Part I: Total Drug Exposure (Area Under the Concentration Curve, AUC[0-24 Hours])
µM*hrVorinostat
Day 1 (n=6)4.59 ± 2.34
Day 28 (n=5)5.59 ± 1.24
PrimaryPart I: Number of Participants Experiencing Dose Limiting Toxicity (DLT)

A DLT was defined as any of the following (per Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0): * Grade 3 (severe)-4 (life-threatening) neutropenia with fever ≥ 38.5ºC * Grade 3-4 neutropenia with an infection requiring antibiotic or antifungal treatment * Grade 4 neutropenia lasting at least 5 days * Grade 4 thrombocytopenia * Other Grade 4 hematologic toxicity, including a decrease in hemoglobin, only at the discretion of the principal investigator * Grade 3 or 4 non-hematologic event, except which are manageable by supportive care or non-prohibited therapies

Time frame:
Day 1 to Day 28
Reported as:
Number · participants
Part I: Number of Participants Experiencing Dose Limiting Toxicity (DLT)
participantsVorinostat
Part I: Number of Participants Experiencing Dose Limiting Toxicity (DLT)1
SecondaryPart I: Maximum Drug Concentration (Cmax)

Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.

Time frame:
Days 1 & 28 of Cycle 1
Reported as:
Geometric mean · µM
Part I: Maximum Drug Concentration (Cmax)
µMVorinostat
Day 1 (n=6)0.83 ± 0.37
Day 28 (n=5)1.17 ± 0.37
SecondaryPart I: Time at Which Cmax Occurs (Tmax)

Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.

Time frame:
Days 1 & 28 of Cycle 1
Reported as:
Median · hours
Part I: Time at Which Cmax Occurs (Tmax)
hoursVorinostat
Day 1 (n=6)2.91 (2.00 to 6.00)
Day 28 (n=5)3.73 (2.93 to 4.28)
SecondaryPart I: The Amount of Time it Takes for the Drug Concentration to Decrease by Half (T1/2)

Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.

Time frame:
Days 1 & 28 of Cycle 1
Reported as:
Geometric mean · hours
Part I: The Amount of Time it Takes for the Drug Concentration to Decrease by Half (T1/2)
hoursVorinostat
Day 1 (n=5)1.94 ± 1.30
Day 28 (n=4)2.30 ± 1.10

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat—3/10 (30%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventVorinostat
InfectionInfections and infestations2/10
NauseaGastrointestinal disorders1/10
VomitingGastrointestinal disorders1/10
Cellulitis streptococcalInfections and infestations1/10
Most frequent other events
Showing 10 of 89
Most frequent other events
EventVorinostat
ThrombocytopeniaBlood and lymphatic system disorders8/10
NauseaGastrointestinal disorders6/10
AnorexiaMetabolism and nutrition disorders6/10
MalaiseGeneral disorders5/10
HypoalbuminaemiaMetabolism and nutrition disorders5/10
DiarrhoeaGastrointestinal disorders4/10
VomitingGastrointestinal disorders4/10
FatigueGeneral disorders4/10
PyrexiaGeneral disorders4/10
HypermagnesaemiaMetabolism and nutrition disorders4/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vorinostat
Mean55.5 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat
Female2
Male8
Region of Enrollment
Region of Enrollment(participants)Vorinostat
Japan10
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wada H, Tsuboi R, Kato Y, Sugaya M, Tobinai K, Hamada T, Shimamoto T, Noguchi K, Iwatsuki K. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. J Dermatol. 2012 Oct;39(10):823-8. doi: 10.1111/j.1346-8138.2012.01554.x. Epub 2012 Apr 16. PubMed 22506596 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 13, 2008
Start
Aug 2008
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Jul 4, 2012
Last update
Apr 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00771472
Responsible party
Sponsor
First posted
Oct 13, 2008
Start date
Aug 2008
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Jul 4, 2012
Last update
Apr 21, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion